TargeGen Funding Round

7/13/2007

Venture Equity

$40,000,000

Series D

TargeGen's most advanced drug candidate is TG100801, a topical (eye drop), multi-target kinase inhibitor for the treatment of macular degeneration, diabetic macular edema and diabetic retinopathy. TargeGen expects to initiate Phase II clinical trials in macular degeneration patients with TG100801 by the end of this month. Additionally, TargeGen is developing TG101348, a Jak2 inhibitor, for the treatment of myeloproliferative diseases including myelofibrosis with myeloid metaplasia, polycythemia vera and essential thrombocytopenia. Patient trials with TG101348 are planned for early 2008. TargeGen has additional compounds targeting inflammatory and ocular diseases in pre-clinical development.

Acquired or Merged

Biopharmaceutical

9380 Judicial Drive
San Diego, CA 92121
USA

TargeGen, Inc. is a privately held, vascular biology-focused, biopharmaceutical company based in San Diego, CA. TargeGen is developing novel small molecule therapeutics to treat cancer and ischemic diseases (heart attack, stroke) by targeting certain biochemical processes associated with disease related changes in vascular permeability and vascular proliferation.